Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Saniona AB (publ)    SANION   SE0005794617

SANIONA AB (PUBL)

(SANION)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Saniona publ : Scandion Oncology announces that one of its founders, Saniona, has reduced its shareholding to below 10% of the total share amount

share with twitter share with LinkedIn share with facebook
08/01/2020 | 07:15am EDT

Scandion Oncology A/S ("Scandion Oncology") announces that Saniona has reduced its ownership stake in Scandion Oncology A/S to below 10%. Saniona, together with CEO Nils Brünner and CSO Jan Stenvang initially founded Scandion Oncology A/S in 2017. After the last capital raise in June 2019, Saniona owned approximately 18% of Scandion Oncology. Proceeds from sales of shares will be used to continue Saniona's advancement of their pipeline, including mid/late-stage clinical trials with Tesomet.

For further information regarding Scandion Oncology, please contact:

Nils Brünner, CEO

Phone: +45 26 14 47 08

E-mail: nb@scandiononcology.com

This information is information that Scandion Oncology is obliged to publish in accordance to the EU Market Abuse Regulation. The information was provided by the contact person above for publication on August 1, 2020.

Scandion Oncology A/S is a biotechnology company that addresses and targets one of the greatest challenges in modern oncology - the effective treatment of cancer which contains chemotherapy-resistant cells or which has developed resistance to a previously prescribed cancer-fighting drug. In preclinical in vitro studies, SCO-101 restores chemotherapy sensitivity in resistant cancer cells. Moreover, in animal studies, the company's leading candidate drug, SCO-101, significantly enhances the efficacy of certain standard cancer treatments when given in combination. Scandion Oncology is now in clinical phase II trials with its lead compound, SCO-101, in patients with chemotherapy-resistant colorectal cancer. Scandion Oncology was listed on Spotlight Stock Market, Sweden in November 2018. For further information, please see: www.scandiononcology.com.

https://news.cision.com/scandion-oncology-a-s/r/scandion-oncology-announces-that-one-of-its-founders--saniona--has-reduced-its-shareholding-to-below,c3162821

(c) 2020 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
Latest news on SANIONA AB (PUBL)
01:00aSaniona successfully raises USD 65 million (approximately SEK 567 million) in..
GL
08/01SANIONA PUBL : Scandion Oncology announces that one of its founders, Saniona, ha..
AQ
07/10BIOSTOCK :  Saniona's CEO has highflying plans
AQ
06/30SANIONA PUBL : Change in numbers of shares and votes in Saniona AB (publ)
AQ
06/22SANIONA PUBL : Scandion Oncology announces that one of its founders, Saniona, ha..
AQ
06/22Saniona raises SEK 22 million through sales of shares in Scandion Oncology
GL
06/09Saniona Receives Positive Feedback from FDA on Regulatory Path for Tesomet in..
GL
05/26Saniona announces outcome of warrant exercise
GL
05/22INITIATOR PHARMA : 1 quarter report 2020
AQ
05/11BIOSTOCK :  Saniona trailblazing towards market approval
AQ
More news
Financials
Sales 2020 87,0 M 9,95 M 9,95 M
Net income 2020 -16,0 M -1,83 M -1,83 M
Net cash 2020 68,0 M 7,78 M 7,78 M
P/E ratio 2020 -69,6x
Yield 2020 -
Capitalization 1 121 M 128 M 128 M
EV / Sales 2020 12,1x
EV / Sales 2021 28,8x
Nbr of Employees 22
Free-Float 71,7%
Chart SANIONA AB (PUBL)
Duration : Period :
Saniona AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANIONA AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
 
Mean consensus -
Number of Analysts 1
Average target price 110,00 SEK
Last Close Price 36,90 SEK
Spread / Highest target 198%
Spread / Average Target 198%
Spread / Lowest Target 198%
EPS Revisions
Managers
NameTitle
Rami Levin President & Chief Executive Officer
Joseph Donald deBethizy Chairman
Anita Milland Chief Financial Officer
Palle Christophersen Chief Scientific Officer
Rudolf A. Baumgartner Chief Medical Officer & Head-Clinical Development
Sector and Competitors
1st jan.Capitalization (M$)
SANIONA AB (PUBL)43.58%128
GILEAD SCIENCES, INC.6.73%86 946
VERTEX PHARMACEUTICALS24.68%71 105
REGENERON PHARMACEUTICALS65.18%65 265
WUXI APPTEC CO., LTD.70.06%38 070
GENMAB A/S55.18%23 785